Report Summary
The Obesity Crisis and Social Media Influence
Sep 1, 2023
Background
The escalating rates of obesity in the United States and Canada present a significant and growing public health epidemic, with around 42% of the US population and 27% of the Canadian population affected. Obesity, characterized by a body mass index (BMI) of ≥ 30 kg/m2, is a chronic disease associated with various health risks, including type 2 diabetes, cancer, high blood pressure, stroke, heart disease, and arthritis. Beyond its physical impact, obesity is stigmatized, perpetuating misconceptions and stereotypes that contribute to discrimination in various societal domains. The estimated annual medical cost of obesity in the US is nearly $173 billion.
Method
KNIGHTLABS conducted a topic-based social media analysis using both qualitative and quantitative methods to analyze a total of 61,165 posts. An exhaustive list of keywords, URLs, and hashtags was developed and tested to collect relevant data for a six-month historical period from January 1 to June 31, 2023. Filters were applied to limit the analysis to the target audience and relevant topics.
Trending Topics
Weight loss medication: Popular medications semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have gained considerable attention in the media as the newest weight loss ‘miracle’ cures.
Childhood obesity: The prevalence of childhood obesity in the US and Canada has been steadily increasing and is considered a public health issue. Childhood obesity can lead to various long term health concerns, both physical and psychological.
Body Mass Index (BMI): BMI was criticized by dietitians and nutrition experts as well as some HCPs for not being an accurate measure of obesity, as well as having racist implications.
Audience
Within this report, we have pinpointed 10,506 authors and identified three distinct segments within the online obesity audience:
HCPs: Endocrinologists, bariatric surgeons, and pharmacists
Patients: Patients with obesity and the people caring for them
Dietitians and Nutritionists: Registered dietitians and nutrition practitioners
Treatment
Discussions on obesity treatments primarily revolved around surgery, endoscopy, pharmacotherapy, and lifestyle changes
Surgery: Popular surgeries include gastric bypass, gastric sleeve, and adjustable gastric band. Endoscopic options, like the gastric balloon and endoscopic sleeve gastroplasty, also gained attention.
Pharmacotherapies: GLP-1 agonists such as semaglutide and liraglutide, dominated discussions, driven by the popularity of drugs like Ozempic, Wegovy, and Mounjaro.
Bariatric surgery: Bariatric surgeries were common, while endoscopy saw comparatively fewer mentions, likely due to its recent introduction in obesity treatment.
Lifestyle modifications: First line therapy for patients with obesity, which include diet, exercise, and behaviour therapy.
Competitor Analysis
Semaglutide (Ozempic, Wegovy) was the most discussed medication, followed by Tirzepatide (Mounjaro). These medications were trending due their recent popularity in the media with celebrities using it for quick weight loss.
Platform & Channels
Twitter emerged as the primary platform, widely utilized by healthcare professionals (HCPs) and patients alike. HCPs engaged in knowledge-sharing, research dissemination, and conference interactions, while patients shared weight-loss journeys and treatment experiences.
Other platforms have been instrumental for patients sharing weight loss stories and techniques.
Unlock the full insight!
Our obesity report provides a comprehensive analysis of online conversations, offering crucial insights into the digital landscape of obesity. Contact us to understand the dynamics of netizens in this space to empower your marketing strategies. This report not only unveils the current landscape but also identifies market challenges and areas of opportunity, giving you a strategic edge in navigating the obesity online landscape.
For tailored research solutions, connect with us at www.klabs.com or call us at +1 855-570-3646.
Background
The escalating rates of obesity in the United States and Canada present a significant and growing public health epidemic, with around 42% of the US population and 27% of the Canadian population affected. Obesity, characterized by a body mass index (BMI) of ≥ 30 kg/m2, is a chronic disease associated with various health risks, including type 2 diabetes, cancer, high blood pressure, stroke, heart disease, and arthritis. Beyond its physical impact, obesity is stigmatized, perpetuating misconceptions and stereotypes that contribute to discrimination in various societal domains. The estimated annual medical cost of obesity in the US is nearly $173 billion.
Method
KNIGHTLABS conducted a topic-based social media analysis using both qualitative and quantitative methods to analyze a total of 61,165 posts. An exhaustive list of keywords, URLs, and hashtags was developed and tested to collect relevant data for a six-month historical period from January 1 to June 31, 2023. Filters were applied to limit the analysis to the target audience and relevant topics.
Trending Topics
Weight loss medication: Popular medications semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have gained considerable attention in the media as the newest weight loss ‘miracle’ cures.
Childhood obesity: The prevalence of childhood obesity in the US and Canada has been steadily increasing and is considered a public health issue. Childhood obesity can lead to various long term health concerns, both physical and psychological.
Body Mass Index (BMI): BMI was criticized by dietitians and nutrition experts as well as some HCPs for not being an accurate measure of obesity, as well as having racist implications.
Audience
Within this report, we have pinpointed 10,506 authors and identified three distinct segments within the online obesity audience:
HCPs: Endocrinologists, bariatric surgeons, and pharmacists
Patients: Patients with obesity and the people caring for them
Dietitians and Nutritionists: Registered dietitians and nutrition practitioners
Treatment
Discussions on obesity treatments primarily revolved around surgery, endoscopy, pharmacotherapy, and lifestyle changes
Surgery: Popular surgeries include gastric bypass, gastric sleeve, and adjustable gastric band. Endoscopic options, like the gastric balloon and endoscopic sleeve gastroplasty, also gained attention.
Pharmacotherapies: GLP-1 agonists such as semaglutide and liraglutide, dominated discussions, driven by the popularity of drugs like Ozempic, Wegovy, and Mounjaro.
Bariatric surgery: Bariatric surgeries were common, while endoscopy saw comparatively fewer mentions, likely due to its recent introduction in obesity treatment.
Lifestyle modifications: First line therapy for patients with obesity, which include diet, exercise, and behaviour therapy.
Competitor Analysis
Semaglutide (Ozempic, Wegovy) was the most discussed medication, followed by Tirzepatide (Mounjaro). These medications were trending due their recent popularity in the media with celebrities using it for quick weight loss.
Platform & Channels
Twitter emerged as the primary platform, widely utilized by healthcare professionals (HCPs) and patients alike. HCPs engaged in knowledge-sharing, research dissemination, and conference interactions, while patients shared weight-loss journeys and treatment experiences.
Other platforms have been instrumental for patients sharing weight loss stories and techniques.
Unlock the full insight!
Our obesity report provides a comprehensive analysis of online conversations, offering crucial insights into the digital landscape of obesity. Contact us to understand the dynamics of netizens in this space to empower your marketing strategies. This report not only unveils the current landscape but also identifies market challenges and areas of opportunity, giving you a strategic edge in navigating the obesity online landscape.
For tailored research solutions, connect with us at www.klabs.com or call us at +1 855-570-3646.
Background
The escalating rates of obesity in the United States and Canada present a significant and growing public health epidemic, with around 42% of the US population and 27% of the Canadian population affected. Obesity, characterized by a body mass index (BMI) of ≥ 30 kg/m2, is a chronic disease associated with various health risks, including type 2 diabetes, cancer, high blood pressure, stroke, heart disease, and arthritis. Beyond its physical impact, obesity is stigmatized, perpetuating misconceptions and stereotypes that contribute to discrimination in various societal domains. The estimated annual medical cost of obesity in the US is nearly $173 billion.
Method
KNIGHTLABS conducted a topic-based social media analysis using both qualitative and quantitative methods to analyze a total of 61,165 posts. An exhaustive list of keywords, URLs, and hashtags was developed and tested to collect relevant data for a six-month historical period from January 1 to June 31, 2023. Filters were applied to limit the analysis to the target audience and relevant topics.
Trending Topics
Weight loss medication: Popular medications semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have gained considerable attention in the media as the newest weight loss ‘miracle’ cures.
Childhood obesity: The prevalence of childhood obesity in the US and Canada has been steadily increasing and is considered a public health issue. Childhood obesity can lead to various long term health concerns, both physical and psychological.
Body Mass Index (BMI): BMI was criticized by dietitians and nutrition experts as well as some HCPs for not being an accurate measure of obesity, as well as having racist implications.
Audience
Within this report, we have pinpointed 10,506 authors and identified three distinct segments within the online obesity audience:
HCPs: Endocrinologists, bariatric surgeons, and pharmacists
Patients: Patients with obesity and the people caring for them
Dietitians and Nutritionists: Registered dietitians and nutrition practitioners
Treatment
Discussions on obesity treatments primarily revolved around surgery, endoscopy, pharmacotherapy, and lifestyle changes
Surgery: Popular surgeries include gastric bypass, gastric sleeve, and adjustable gastric band. Endoscopic options, like the gastric balloon and endoscopic sleeve gastroplasty, also gained attention.
Pharmacotherapies: GLP-1 agonists such as semaglutide and liraglutide, dominated discussions, driven by the popularity of drugs like Ozempic, Wegovy, and Mounjaro.
Bariatric surgery: Bariatric surgeries were common, while endoscopy saw comparatively fewer mentions, likely due to its recent introduction in obesity treatment.
Lifestyle modifications: First line therapy for patients with obesity, which include diet, exercise, and behaviour therapy.
Competitor Analysis
Semaglutide (Ozempic, Wegovy) was the most discussed medication, followed by Tirzepatide (Mounjaro). These medications were trending due their recent popularity in the media with celebrities using it for quick weight loss.
Platform & Channels
Twitter emerged as the primary platform, widely utilized by healthcare professionals (HCPs) and patients alike. HCPs engaged in knowledge-sharing, research dissemination, and conference interactions, while patients shared weight-loss journeys and treatment experiences.
Other platforms have been instrumental for patients sharing weight loss stories and techniques.
Unlock the full insight!
Our obesity report provides a comprehensive analysis of online conversations, offering crucial insights into the digital landscape of obesity. Contact us to understand the dynamics of netizens in this space to empower your marketing strategies. This report not only unveils the current landscape but also identifies market challenges and areas of opportunity, giving you a strategic edge in navigating the obesity online landscape.
For tailored research solutions, connect with us at www.klabs.com or call us at +1 855-570-3646.
